Composition containing BTK inhibitor, and use thereof

WO2024235166A1PCT designated stage expired Publication Date: 2024-11-21WUHAN HUMANWELL INNOVATIVE DRUG RES & DEV CENT LTD CO
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/092688
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-11
Publication Date
2024-11-21

Smart Images

  • Figure PCTCN2024092688-FTAPPB-I100001
    Figure PCTCN2024092688-FTAPPB-I100001
  • Figure PCTCN2024092688-FTAPPB-I100002
    Figure PCTCN2024092688-FTAPPB-I100002
  • Figure PCTCN2024092688-FTAPPB-I100003
    Figure PCTCN2024092688-FTAPPB-I100003
Patent Text Reader

Abstract

A composition containing a BTK inhibitor, and a use thereof. The composition comprises (R)-1-(1-acryloyl piperidine-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Compositions containing BTK inhibitors and uses thereof

[0001] Priority information

[0002] This application claims priority and benefits of patent application 202310539559.0 filed with the State Intellectual Property Office of China on May 12, 2023, and incorporates the entire text of it herein by reference. Technical Field

[0003] The present invention relates to a composition containing a BTK inhibitor and its use. Background Art

[0004] Irreversible Bruton's Tyrosine Kinase (BTK) inhibitors can block multiple immune signaling pathways in immune cells other than T cells and terminally differentiated plasma cells, such as blocking B cell receptors in B cells, inhibiting plasma cell differentiation and antibody production, blocking IgG-mediated FCGR activation, phagocytosis and inflammatory mediators in monocytes and macrophages, blocking IgE-mediated FCR activation and degranulation in mast cells and basophils, and inhibiting cell activation, recruitment, and oxidation in neutrophils.

[0005] The pathogenesis of urticaria can be divided into two categories: allergic and non-allergic. The allergic reaction is primarily type I, in which antigens and antibodies (IgE) act on mast cells and basophils, causing their granules to detach and releasing a series of chemical mediators (histamine and histamine-like substances). This leads to capillary dilation, increased permeability, smooth muscle spasm, and increased glandular secretion. The non-allergic reaction is caused by certain biological, chemical, and physical factors that directly act on mast cells and basophils, causing them to release granules. Studies have demonstrated in human mast cells that BTK is essential for Fc receptor signaling. BTK inhibitors can inhibit the FcγR pathway, thereby suppressing IgE-induced mast cell degranulation and the release of histamine and inflammatory factors. BTK-targeted drugs have been shown to be effective inhibitors of IgE-dependent histamine release in human basophils in both non-allergic and allergic subjects.

[0006] Therefore, there is an urgent need to develop a composition containing a BTK inhibitor for treating BTK-related immune system diseases.

[0007] Summary of the Invention

[0008] The present invention aims to at least partially address at least one of the technical problems existing in the prior art. To this end, the present invention provides a composition containing a BTK inhibitor, which has high stability and can be used to treat immune system diseases, such as chronic spontaneous urticaria in adults.

[0009] In one aspect of the present invention, the present invention provides a composition. According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof. The composition of the present invention uses (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof (referred to herein as the API or Compound (I)) as an active ingredient, which can be used to prevent or treat immune system diseases, such as chronic spontaneous urticaria in adults.

[0010] According to an embodiment of the present invention, the above-mentioned composition may further include at least one of the following technical features:

[0011] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 1 to 800 mg.

[0012] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 5 to 800 mg.

[0013] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 10 to 800 mg.

[0014] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 5 to 100 mg. According to an embodiment of the present invention, the mass percentage of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof in the composition is about 1% to 40%, preferably about 4% to 35%.

[0015] According to an embodiment of the present invention, the composition further comprises a pharmaceutically acceptable excipient.

[0016] According to an embodiment of the present invention, the pharmaceutically acceptable excipient includes a filler. Thus, combining the active ingredient with the filler can effectively overcome the problem of reduced stability of the composition, and the composition has advantages such as high stability. According to an embodiment of the present invention, the filler includes at least one of pregelatinized starch, mannitol, microcrystalline cellulose, and lactose.

[0017] According to an embodiment of the present invention, the filler is pregelatinized starch.

[0018] According to an embodiment of the present invention, the filler is mannitol.

[0019] According to an embodiment of the present invention, the filler is selected from microcrystalline cellulose and / or mannitol.

[0020] According to an embodiment of the present invention, the filler is microcrystalline cellulose and optionally mannitol.

[0021] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is approximately (1-40):(60-99).

[0022] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is approximately (4-35):(61-91).

[0023] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is approximately (16-35):(61-79).

[0024] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is approximately (4-10):(80-91).

[0025] According to an embodiment of the present invention, the pharmaceutically acceptable excipient further includes at least one of a disintegrant, a lubricant, a surfactant and a binder.

[0026] According to an embodiment of the present invention, the disintegrant is selected from at least one of cross-linked sodium carboxymethyl cellulose, sodium starch glycolate and cross-linked polyvinylpyrrolidone.

[0027] According to an embodiment of the present invention, the disintegrant is cross-linked sodium carboxymethyl cellulose.

[0028] According to an embodiment of the present invention, the lubricant is selected from at least one of magnesium stearate, calcium stearate and talc.

[0029] According to an embodiment of the present invention, the lubricant is magnesium stearate.

[0030] According to an embodiment of the present invention, the binder is selected from at least one of hypromellose, povidone K30 and hydroxypropyl cellulose.

[0031] According to an embodiment of the present invention, the binder includes hypromellose and / or povidone K30.

[0032] According to an embodiment of the present invention, the surfactant is selected from sodium lauryl sulfate and / or Tween 80.

[0033] According to an embodiment of the present invention, the surfactant is sodium lauryl sulfate.

[0034] According to an embodiment of the present invention, in the composition, the surfactant and the binder are present simultaneously.

[0035] According to an embodiment of the present invention, the composition does not include micro powder silica gel.

[0036] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the disintegrant is approximately (1-40):(1-10), preferably approximately (4-35):(4-6).

[0037] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the lubricant is approximately (1-40):(0.1-1), preferably (4-35):(0.1-0.6).

[0038] According to an embodiment of the present invention, the weight ratio of the surfactant to the binder is approximately (0.1-1):(1-5).

[0039] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof and the surfactant is approximately (1-40):(0.1-1), preferably approximately (4-35):(0.4-0.6).

[0040] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the binder is approximately (1-40):(1-5), preferably approximately (4-35):(1-2).

[0041] According to an embodiment of the present invention, the composition is an oral preparation.

[0042] According to an embodiment of the present invention, the oral preparation is a capsule or a tablet.

[0043] According to an embodiment of the present invention, the composition is a capsule.

[0044] According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant and a lubricant.

[0045] According to an embodiment of the present invention, the composition does not include a surfactant.

[0046] According to an embodiment of the present invention, the composition includes: about 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 61 to 91 parts by weight of a filler, about 4 to 6 parts by weight of a disintegrant, and about 0.1 to 0.6 parts by weight of a lubricant.

[0047] According to an embodiment of the present invention, the composition includes: about 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 61 to 91 parts by weight of pregelatinized starch, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.1 to 0.6 parts by weight of magnesium stearate.

[0048] According to an embodiment of the present invention, the composition includes: about 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 88 to 91 parts by weight of mannitol, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.1 to 0.6 parts by weight of magnesium stearate.

[0049] According to an embodiment of the present invention, the composition includes: about 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 88 to 91 parts by weight of microcrystalline cellulose, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.1 to 0.6 parts by weight of magnesium stearate.

[0050] According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant, a binder, a surfactant and a lubricant.

[0051] According to an embodiment of the present invention, the composition includes: about 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 80 to 90 parts by weight of a filler, about 4 to 6 parts by weight of a disintegrant, about 1 to 2 parts by weight of a binder, about 0.4 to 0.6 parts by weight of a surfactant, and about 0.1 to 0.6 parts by weight of a lubricant.

[0052] According to an embodiment of the present invention, the composition includes: about 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 15 to 20 parts by weight of microcrystalline cellulose, about 65 to 70 parts by weight of mannitol, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, about 1 to 2 parts by weight of hypromellose, about 0.4 to 0.6 parts by weight of sodium lauryl sulfate, and about 0.1 to 0.6 parts by weight of magnesium stearate.

[0053] In another aspect of the present invention, the present invention proposes a capsule. According to an embodiment of the present invention, the capsule is composed of the following components: about 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 61 to 91 parts by weight of one of pregelatinized starch, mannitol and microcrystalline cellulose, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.1 to 0.6 parts by weight of magnesium stearate. The composition of the present invention has the advantages of high stability, and its total impurity content is ≤5.0% when stored at 60°C for 10 days. It can be used to prevent or treat immune system diseases, such as chronic spontaneous urticaria in adults.

[0054] According to an embodiment of the present invention, the capsule is composed of the following components: about 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 88 to 91 parts by weight of pregelatinized starch, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.4 to 0.6 parts by weight of magnesium stearate.

[0055] According to an embodiment of the present invention, the capsule is composed of the following components: about 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 88 to 91 parts by weight of microcrystalline cellulose, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.4 to 0.6 parts by weight of magnesium stearate.

[0056] According to an embodiment of the present invention, the capsule is composed of the following components: about 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 88 to 91 parts by weight of mannitol, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.4 to 0.6 parts by weight of magnesium stearate.

[0057] According to an embodiment of the present invention, the capsule is composed of the following components: about 16 to 17 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 78 to 79 parts by weight of pregelatinized starch, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.1 to 0.3 parts by weight of magnesium stearate.

[0058] According to an embodiment of the present invention, the capsule is composed of the following components: about 28 to 34 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 61 to 67 parts by weight of pregelatinized starch, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.1 to 0.3 parts by weight of magnesium stearate.

[0059] In another aspect of the present invention, the present invention proposes a capsule. According to an embodiment of the present invention, the capsule is composed of the following components: about 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 15 to 20 parts by weight of microcrystalline cellulose, about 65 to 70 parts by weight of mannitol, about 4 to 6 parts by weight of cross-linked carboxymethyl cellulose sodium, about 1 to 2 parts by weight of hypromellose, about 0.4 to 0.6 parts by weight of sodium lauryl sulfate, and about 0.1 to 0.6 parts by weight of magnesium stearate. The composition of the present invention has the advantages of high stability, and its total impurity content is ≤5.0% when stored at 60°C for 10 days. It can be used to prevent or treat immune system diseases, such as chronic spontaneous urticaria in adults.

[0060] In another aspect of the present invention, the present invention provides a use of the aforementioned composition or the aforementioned capsule in preparing a medicament for treating and / or preventing immune system diseases.

[0061] In another aspect of the present invention, the present invention provides a use of the aforementioned composition or the aforementioned capsule in treating and / or preventing immune system diseases.

[0062] In another aspect of the present invention, the present invention provides the aforementioned composition or capsule for use in treating and / or preventing immune system diseases.

[0063] According to an embodiment of the present invention, the uses described in the above three aspects may further include at least one of the following technical features:

[0064] According to an embodiment of the present invention, the immune system disease includes an autoimmune disease and / or a skin allergy disease.

[0065] According to an embodiment of the present invention, the autoimmune disease includes autoimmune disease, urticaria, skin inflammation and / or eczema.

[0066] According to an embodiment of the present invention, the urticaria is chronic spontaneous urticaria.

[0067] In another aspect, the present invention provides a method for treating and / or preventing immune system diseases. According to an embodiment of the present invention, the method comprises: administering a pharmaceutically acceptable amount of the aforementioned composition or capsule to a subject.

[0068] According to an embodiment of the present invention, the immune system disease includes an autoimmune disease and / or a skin allergy disease.

[0069] According to an embodiment of the present invention, the autoimmune disease includes autoimmune disease, urticaria, skin inflammation and / or eczema.

[0070] According to an embodiment of the present invention, the urticaria is chronic spontaneous urticaria.

[0071] Additional aspects and advantages of the present invention will be set forth in part in the description which follows and, in part, will be obvious from the description which follows, or may be learned by practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0072] The above and / or additional aspects and advantages of the present invention will become apparent and readily understood from the following description of the embodiments with reference to the accompanying drawings, in which:

[0073] FIG1 shows the dissolution results of Formulations 1 to 5 in Example 1 of the present invention;

[0074] FIG2 shows the dissolution results of Prescription A, Prescription B, and Prescription C-2 in Example 3 of the present invention;

[0075] FIG3 is a graph showing the C of the raw material capsule after a single administration of each dosage group in the clinical trial of Test Example 1 of the present invention. max correlation with drug substance dosage;

[0076] FIG4 is the AUC of the raw material capsule after a single administration of each dose group (10-100 mg) in the clinical trial of Test Example 1 of the present invention 0-t correlation with drug substance dosage;

[0077] FIG5 is the AUC of the raw material capsule after a single administration of each dose group (200-800 mg) in the clinical trial of Test Example 1 of the present invention 0-t correlation with drug substance dosage;

[0078] FIG6 shows the change in BTK target site occupancy over time for each dosage group of the API capsule in the clinical trial of Test Example 1 of the present invention;

[0079] FIG7 shows all subjects C in the clinical trial of Test Example 1 of the present invention. max Curve fitting with BTK target occupancy max;

[0080] FIG8 is the AUC of all subjects in the clinical trial of Test Example 1 of the present invention last Curve fitting with BTK target occupancy max. DETAILED DESCRIPTION

[0081] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.

[0082] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood to indicate or imply relative importance or implicitly specify the number of the technical features indicated. Therefore, features defined as "first" or "second" may explicitly or implicitly include one or more of such features. Furthermore, in the description of the present invention, unless otherwise specified, "plurality" means two or more.

[0083] Where a numerical range is provided, it is understood that, unless the context clearly indicates otherwise, intervening values ​​between the upper and lower limits of the range and any other stated or intervening values ​​in the range are encompassed within the present invention, to the tenth of the unit of the lower limit. The upper and lower limits of these smaller ranges may be independently included in the smaller range and are also encompassed within the present invention, subject to any specifically excluded limitations within the range. Where the range includes one or both of the limits, ranges excluding either or both of those that include the limits are also encompassed within the present invention. Certain ranges are provided herein with values ​​preceded by the term "about". The term "about" is used herein to provide literal support for the exact value preceding it and for values ​​that are close to or approximately preceded by the term. In determining whether a value is close to or approximately a specifically stated value, the close or approximate unstated value may be a value that, in the context in which it is provided, provides a substantial equivalence to the specifically stated value. The term "about" or "approximately" refers to the acceptable error for a particular value as determined by one skilled in the art, which depends in part on how the value is measured or determined. In certain embodiments, the term "about" or "approximately" refers to within 1, 2, 3, or 4 standard deviations. In certain embodiments, the term "about" or "approximately" means within 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, or 0.05% of a given value or range.

[0084] The term "include" or "comprising" is an open expression, that is, including the contents specified in the present invention, but not excluding other contents.

[0085] The terms "optionally," "optional," or "optionally" mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0086] The term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammal to be treated therewith. Preferably, the "pharmaceutically acceptable" herein means approved by federal regulatory agencies or national governments or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopeia for use in animals, particularly humans.

[0087] The term "pharmaceutically acceptable salt" refers to organic and inorganic salts of Compound (I) of the present invention. Pharmaceutically acceptable salts are well known in the art. In some embodiments, the pharmaceutically acceptable salts of the present invention include, but are not limited to, hydrochloride, benzenesulfonate, p-toluenesulfonate, sulfate, hydrobromide, and the like.

[0088] For the excipients and other pharmaceutically acceptable excipients or processes mentioned herein, reference can be made to a large number of literatures on this subject and will not be described in detail here.

[0089] As used herein, the term "treatment" refers to a method for obtaining a desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in individuals who are susceptible to the disease but have not yet been diagnosed with the disease; (b) inhibiting the disease, such as arresting the development of the disease; or (c) alleviating the disease, such as alleviating the symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug or compound (I) to an individual to treat, cure, alleviate, improve, reduce or inhibit the individual's disease, including but not limited to administering a drug containing compound (I) as described herein to an individual in need.

[0090] The present invention provides a composition containing a BTK inhibitor and its use, which will be described in detail below.

[0091] Composition

[0092] In one aspect of the present invention, the present invention provides a composition. According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof. The composition of the present invention uses (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof as an active ingredient, which can be used to prevent or treat immune system diseases, such as chronic spontaneous urticaria in adults.

[0093] As used herein, the term "active ingredient" or "active agent" refers to a substance used in therapy (e.g., human therapy, veterinary therapy), including both prophylactic and therapeutic treatments. An active ingredient includes any substance used as a drug to treat, prevent, delay, alleviate, or ameliorate a disease, condition, or disorder.

[0094] The structure of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one is shown below:

[0095] According to an embodiment of the present invention, the above-mentioned composition may further include at least one of the following technical features:

[0096] According to an embodiment of the present invention, the composition of the present invention contains a suitable amount of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof. The suitable amount is an effective dose of the compound (I), which is safe and effective.

[0097] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 1 to 800 mg.

[0098] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 5 to 800 mg.

[0099] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 10 to 800 mg.

[0100] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 5 to 100 mg.

[0101] In some optional embodiments of the present invention, in the composition, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 1-5 mg, 1-10 mg, 1-25 mg, 1-50 mg, 1-100 mg, 1-200 mg, 1-400 mg, 1-600 mg, 1-800 mg, 5-10 mg, 5-25 mg, 5-50 mg, 5-100 mg, 5-200 mg, 5-400 mg, 5-600 mg, 5-800 mg, 10-25 mg, 10-5 0mg, 10-100mg, 10-200mg, 10-400mg, 10-600mg, 10-800mg, 25-50mg, 25-100mg, 25-200mg, 25-400mg, 25-600mg, 25-800mg, 50-100mg, 50-200mg, 50- 400mg, 50-600mg, 50-800mg, 100-200mg, 100-400mg, 100-600mg, 100-800mg, 200-400mg, 200-600mg, 200-800mg, 400-600mg, 400-800mg, 600-800mg.

[0102] In some optional embodiments of the present invention, in the composition, the content of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg or 800 mg.

[0103] In some optional embodiments of the present invention, the mass percentage of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof in the composition is approximately 1% to 40%, preferably approximately 4% to 35%.

[0104] In some optional embodiments of the present invention, the mass percentage of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one in the composition is about 1% to 40%, preferably about 4% to 35%, 4% to 6%, 16% to 17%, 28% to 34% or 4% to 10%.

[0105] It should be noted that when the active ingredient in the composition is a pharmaceutically acceptable salt of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one, the content of the salt can be converted according to the molecular weight ratio of the free compound (I) to the corresponding salt.

[0106] According to an embodiment of the present invention, the composition further comprises a pharmaceutically acceptable excipient.

[0107] According to an embodiment of the present invention, the pharmaceutically acceptable excipient includes a filler. Thus, the combination of the active ingredient and the filler can effectively overcome the problem of reduced stability of the composition, and the composition has advantages such as high stability.

[0108] According to an embodiment of the present invention, the filler includes at least one of pregelatinized starch, mannitol, microcrystalline cellulose and lactose.

[0109] According to an embodiment of the present invention, the filler is pregelatinized starch.

[0110] According to an embodiment of the present invention, the filler is mannitol.

[0111] According to an embodiment of the present invention, the filler is microcrystalline cellulose and / or mannitol.

[0112] According to an embodiment of the present invention, the filler is microcrystalline cellulose and optionally mannitol.

[0113] According to an embodiment of the present invention, the filler is microcrystalline cellulose.

[0114] According to an embodiment of the present invention, the filler is microcrystalline cellulose and mannitol.

[0115] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is approximately (1-40):(60-99).

[0116] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is approximately (4-35):(61-91).

[0117] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is approximately (16-35):(61-79).

[0118] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is approximately (4-10):(80-91).

[0119] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is approximately (4-6):(88-91).

[0120] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is approximately (16-17):(78-79).

[0121] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is approximately (28-34):(61-67).

[0122] Thus, the amount and rate of impurities generated during storage of the composition can be effectively reduced, the stability of the composition can be improved, and the storage of the composition can be facilitated.

[0123] According to an embodiment of the present invention, the pharmaceutically acceptable excipients include at least one of a disintegrant, a lubricant, a surfactant, and a binder. By adding the above-mentioned excipients, the stability of the composition can be further improved.

[0124] According to an embodiment of the present invention, the disintegrant is selected from at least one of cross-linked sodium carboxymethyl cellulose, sodium starch glycolate and cross-linked polyvinylpyrrolidone.

[0125] According to an embodiment of the present invention, the disintegrant is cross-linked sodium carboxymethyl cellulose.

[0126] According to an embodiment of the present invention, the lubricant is selected from at least one of magnesium stearate, calcium stearate and talc.

[0127] According to an embodiment of the present invention, the lubricant is magnesium stearate.

[0128] According to an embodiment of the present invention, the binder is selected from at least one of hypromellose, povidone K30 and hydroxypropyl cellulose.

[0129] According to an embodiment of the present invention, the binder includes hypromellose and / or povidone K30.

[0130] According to an embodiment of the present invention, the surfactant is selected from sodium lauryl sulfate and / or Tween 80.

[0131] According to an embodiment of the present invention, the surfactant is sodium lauryl sulfate.

[0132] According to an embodiment of the present invention, in the composition, the surfactant and the binder are present simultaneously.

[0133] According to an embodiment of the present invention, in the composition, the filler is microcrystalline cellulose and mannitol, and the surfactant and the binder are present at the same time.

[0134] According to an embodiment of the present invention, the composition does not include micro powder silica gel.

[0135] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the disintegrant is approximately (1-40):(1-10), for example, (1-40):(1-9), (1-40):(1-8), (1-40):(1-7), (1-40):(1-6), (1-40):(1-5), (1-40):(1-6). :(2~9),(1~40):(2~8),(1~40):(2~7),(1~40):(2~6),(1~40):(2~5),(1~40):(3~9),(1~40):(3~8),(1~40):(3~7),(1~40):(3~6),(1~40):(3~5),(1~40):(4~9),(1~40):(4~8),(1~40):(4~7),(4~35):(4~6),(4~35):(4~5).

[0136] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the lubricant is approximately (1-40):(0.1-1), for example, (1-40):(0.1-0.9), (1-40):(0.1-0.8), (1-40):(0.1-0.7), (4-35):(0.1-0.6), (1-40):(0.1-0.5), (1-40):(0.2-0.9), (1-40):(0. .2~0.8), (1~40): (0.2~0.7), (1~40): (0.2~0.6), (1~40): (0.2~0.5), (1~40): (0.3~0.9), (1~40): (0.3~0.8), (1~40): (0.3~0.7), (1~40): (0.3~0.6), (1~40): (0.3~0.5), (1~40): (0.4~0.9), (1~40): (0.4~0.8), (1~40): (0.4~0.7), (1~40): (0.4~0.6), (1~40): (0.4~0.5).

[0137] According to an embodiment of the present invention, the weight ratio of the surfactant to the binder is approximately (0.1-1):(1-5).

[0138] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the surfactant is approximately (1-40):(0.1-1), for example, (1-40):(0.1-0.9), (1-40):(0.1-0.8), (1-40):(0.1-0.7), (4-35):(0.1-0.6), (1-40):(0.1-0.5), (1-40):(0.2-0.9), (1-40):(0.2-0.8) 、(1~40):(0.2~0.7),(1~40):(0.2~0.6),(1~40):(0.2~0.5),(1~40):(0.3~0.9),(1~40):(0.3~0.8),(1~40):(0.3~0.7),(1~40):(0.3~0.6),(1~40):(0.3~0.5),(1~40):(0.4~0.9),(1~40):(0.4~0.8),(1~40):(0.4~0.7),(1~40):(0.4~0.6),(4~35):(0.4~0.6),(1~40):(0.4~0.5).

[0139] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof and the binder is approximately (1-40):(1-5), for example, (1-40):(1-4), (1-40):(1-3), (4-35):(1-2), (1-40):(2-5), (1-40):(2-4), (1-40):(2-3).

[0140] According to an embodiment of the present invention, the composition is an oral preparation, such as a solid oral preparation.

[0141] In this article, the term "oral preparation" refers to a preparation form that is administered orally and absorbed into the blood through the gastrointestinal tract, including but not limited to tablets, granules, capsules, oral solutions, etc.

[0142] The term "solid oral dosage form" refers to tablets, dispersible tablets, fast-dissolving tablets, rapidly dissolving tablets, fast-melting tablets, orally dissolving tablets, orally melting tablets, orodispersible tablets, lyophilized units, porous tablets, conventional tablets, coated tablets, uncoated tablets, enteric-coated tablets (gastro-resistant tablets), effervescent tablets, soluble tablets, chewable tablets, oral lyophilisates, powders, oral powders, pills, capsules and / or granules. In some embodiments, the solid oral dosage form is a capsule. In some embodiments, the solid oral dosage form is a tablet.

[0143] According to an embodiment of the present invention, the solid oral preparation is a capsule or a tablet.

[0144] According to an embodiment of the present invention, the composition is a capsule.

[0145] According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant and a lubricant.

[0146] According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant, and a lubricant, but does not include a surfactant. This reduces the amount and rate of impurity generation during storage of the composition, improves the stability of the composition, and facilitates storage of the composition.

[0147] According to an embodiment of the present invention, the composition does not include a surfactant.

[0148] According to an embodiment of the present invention, in the composition, the filler is pregelatinized starch, mannitol, microcrystalline cellulose, or lactose, and the composition does not include a surfactant.

[0149] According to an embodiment of the present invention, the composition includes: approximately 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, approximately 61 to 91 parts by weight of a filler, approximately 4 to 6 parts by weight of a disintegrant, and approximately 0.1 to 0.6 parts by weight of a lubricant. This reduces the amount and rate of impurity generation during storage of the composition, improves the stability of the composition, and facilitates storage of the composition.

[0150] In this article, the term "parts by weight" refers to the mass fraction obtained by comparing the mass of a component of the composition with the mass of other components. For example, if the filler content is about 61 to 91 parts by weight, it means that the mass fraction obtained by comparing the mass of the filler with the mass of other components of the composition is about 61 to 91 parts by weight.

[0151] According to an embodiment of the present invention, the composition includes: approximately 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, approximately 61 to 91 parts by weight of pregelatinized starch, approximately 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and approximately 0.1 to 0.6 parts by weight of magnesium stearate. This reduces the amount and rate of impurity generation during storage of the composition, improves the stability of the composition, and facilitates storage of the composition.

[0152] According to an embodiment of the present invention, the composition includes: about 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 88 to 91 parts by weight of pregelatinized starch, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.4 to 0.6 parts by weight of magnesium stearate.

[0153] According to an embodiment of the present invention, the composition includes: about 4 to 5 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 88 to 91 parts by weight of pregelatinized starch, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.4 to 0.6 parts by weight of magnesium stearate.

[0154] According to an embodiment of the present invention, the composition includes: about 16 to 17 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 78 to 79 parts by weight of pregelatinized starch, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.1 to 0.3 parts by weight of magnesium stearate.

[0155] According to an embodiment of the present invention, the composition includes: about 28 to 34 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 61 to 67 parts by weight of pregelatinized starch, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.1 to 0.3 parts by weight of magnesium stearate.

[0156] According to an embodiment of the present invention, the composition includes: approximately 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, approximately 88 to 91 parts by weight of mannitol, approximately 4 to 6 parts by weight of croscarmellose sodium, and approximately 0.1 to 0.6 parts by weight of magnesium stearate. This reduces the amount and rate of impurity generation during storage of the composition, improves the stability of the composition, and facilitates storage of the composition.

[0157] According to an embodiment of the present invention, the composition includes: approximately 4 to 5 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, approximately 88 to 91 parts by weight of mannitol, approximately 4 to 6 parts by weight of croscarmellose sodium, and approximately 0.1 to 0.6 parts by weight of magnesium stearate. This reduces the amount and rate of impurity generation during storage of the composition, improves the stability of the composition, and facilitates storage of the composition.

[0158] According to an embodiment of the present invention, the composition includes: approximately 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, approximately 88 to 91 parts by weight of microcrystalline cellulose, approximately 4 to 6 parts by weight of croscarmellose sodium, and approximately 0.1 to 0.6 parts by weight of magnesium stearate. This reduces the amount and rate of impurity generation during storage of the composition, improves the stability of the composition, and facilitates storage of the composition.

[0159] According to an embodiment of the present invention, the composition includes: approximately 4 to 5 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, approximately 88 to 91 parts by weight of microcrystalline cellulose, approximately 4 to 6 parts by weight of croscarmellose sodium, and approximately 0.1 to 0.6 parts by weight of magnesium stearate. This reduces the amount and rate of impurity generation during storage of the composition, improves the stability of the composition, and facilitates storage of the composition.

[0160] According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant, a binder, a surfactant, and a lubricant. This reduces the amount and rate of impurity generation during storage of the composition, improves the stability of the composition, and facilitates storage of the composition.

[0161] According to an embodiment of the present invention, the composition includes: about 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 80 to 90 parts by weight of a filler, about 4 to 6 parts by weight of a disintegrant, about 1 to 2 parts by weight of a binder, about 0.4 to 0.6 parts by weight of a surfactant, and about 0.1 to 0.6 parts by weight of a lubricant. This reduces the amount and rate of impurities generated during storage of the composition, improves the stability of the composition, and facilitates storage of the composition.

[0162] According to an embodiment of the present invention, the composition includes: about 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 15 to 20 parts by weight of microcrystalline cellulose, about 65 to 70 parts by weight of mannitol, about 4 to 6 parts by weight of croscarmellose sodium, about 1 to 2 parts by weight of hypromellose, about 0.4 to 0.6 parts by weight of sodium lauryl sulfate, and about 0.1 to 0.6 parts by weight of magnesium stearate. Thus, the amount and rate of impurities generated during storage of the composition can be reduced, the stability of the composition can be improved, and the storage of the composition can be facilitated.

[0163] In another aspect of the present invention, the present invention proposes a capsule. According to an embodiment of the present invention, the capsule is composed of the following components: about 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 61 to 91 parts by weight of one of pregelatinized starch, mannitol and microcrystalline cellulose, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.1 to 0.6 parts by weight of magnesium stearate. The composition of the present invention has the advantages of high stability, and its total impurity content is ≤5.0% when stored at 60°C for 10 days. It can be used to prevent or treat immune system diseases, such as chronic spontaneous urticaria in adults.

[0164] According to an embodiment of the present invention, the capsule is composed of the following components: approximately 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, approximately 88 to 91 parts by weight of pregelatinized starch, approximately 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and approximately 0.4 to 0.6 parts by weight of magnesium stearate. This reduces the amount and rate of impurities generated during storage of the capsule, improves the stability of the capsule, and facilitates storage of the capsule.

[0165] According to an embodiment of the present invention, the capsule is composed of the following components: approximately 4 to 5 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, approximately 88 to 91 parts by weight of pregelatinized starch, approximately 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and approximately 0.4 to 0.6 parts by weight of magnesium stearate. This reduces the amount and rate of impurities generated during storage of the capsule, improves the stability of the capsule, and facilitates storage of the capsule.

[0166] According to an embodiment of the present invention, the capsule is composed of the following components: about 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 88 to 91 parts by weight of microcrystalline cellulose, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.4 to 0.6 parts by weight of magnesium stearate.

[0167] According to an embodiment of the present invention, the capsule is composed of the following components: about 4 to 5 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 88 to 91 parts by weight of microcrystalline cellulose, about 4 to 6 parts by weight of cross-linked carboxymethyl cellulose sodium, and about 0.4 to 0.6 parts by weight of magnesium stearate.

[0168] According to an embodiment of the present invention, the capsule is composed of the following components: about 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 88 to 91 parts by weight of mannitol, about 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and about 0.4 to 0.6 parts by weight of magnesium stearate.

[0169] According to an embodiment of the present invention, the capsule is composed of the following components: about 4 to 5 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 88 to 91 parts by weight of mannitol, about 4 to 6 parts by weight of cross-linked carboxymethyl cellulose sodium, and about 0.4 to 0.6 parts by weight of magnesium stearate.

[0170] According to an embodiment of the present invention, the capsule is composed of the following components: approximately 16 to 17 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, approximately 78 to 79 parts by weight of pregelatinized starch, approximately 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and approximately 0.1 to 0.3 parts by weight of magnesium stearate. This reduces the amount and rate of impurity generation during storage of the capsule, improves the stability of the capsule, and facilitates storage of the capsule.

[0171] According to an embodiment of the present invention, the capsule is composed of the following components: approximately 28 to 34 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, approximately 61 to 67 parts by weight of pregelatinized starch, approximately 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and approximately 0.1 to 0.3 parts by weight of magnesium stearate. This reduces the amount and rate of impurities generated during storage of the capsule, improves the stability of the capsule, and facilitates storage of the capsule.

[0172] According to an embodiment of the present invention, the capsule is composed of the following components: approximately 28 to 29 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, approximately 65 to 67 parts by weight of pregelatinized starch, approximately 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and approximately 0.1 to 0.3 parts by weight of magnesium stearate. This reduces the amount and rate of impurities generated during storage of the capsule, improves the stability of the capsule, and facilitates storage of the capsule.

[0173] According to an embodiment of the present invention, the capsule is composed of the following components: approximately 33 to 34 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, approximately 61 to 62 parts by weight of pregelatinized starch, approximately 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and approximately 0.1 to 0.3 parts by weight of magnesium stearate. This reduces the amount and rate of impurities generated during storage of the capsule, improves the stability of the capsule, and facilitates storage of the capsule.

[0174] In another aspect of the present invention, the present invention proposes a capsule. According to an embodiment of the present invention, the capsule is composed of the following components: about 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 15 to 20 parts by weight of microcrystalline cellulose, about 65 to 70 parts by weight of mannitol, about 4 to 6 parts by weight of cross-linked carboxymethyl cellulose sodium, about 1 to 2 parts by weight of hypromellose, about 0.4 to 0.6 parts by weight of sodium lauryl sulfate, and about 0.1 to 0.6 parts by weight of magnesium stearate. The composition of the present invention has the advantages of high stability, and its total impurity content is ≤5.0% when stored at 60°C for 10 days. It can be used to prevent or treat immune system diseases, such as chronic spontaneous urticaria in adults.

[0175] In addition, those skilled in the art will appreciate that the features and advantages described above for the composition are also applicable to the capsule, and will not be described in detail here.

[0176] Pharmaceutical uses

[0177] In another aspect of the present invention, the present invention provides a use of the aforementioned composition or the aforementioned capsule in preparing a medicament for treating and / or preventing immune system diseases.

[0178] In this article, “skin allergic disease” and “skin allergic reaction” are synonymous unless otherwise specified.

[0179] According to an embodiment of the present invention, the immune system disease includes an autoimmune disease and / or a skin allergy disease.

[0180] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis and / or skin allergy disease.

[0181] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis, urticaria, skin inflammation and / or eczema.

[0182] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis and / or urticaria.

[0183] According to an embodiment of the present invention, the skin allergy disease includes urticaria, skin inflammation and / or eczema.

[0184] According to an embodiment of the present invention, the urticaria is chronic spontaneous urticaria.

[0185] Methods for treating or preventing immune system diseases

[0186] In another aspect, the present invention provides a method for treating and / or preventing immune system diseases. According to an embodiment of the present invention, the method comprises: administering a pharmaceutically acceptable amount of the aforementioned composition or capsule to a subject.

[0187] Composition provided by the present invention or capsule can be given to the patient separately, also can be given jointly or co-administered with other active agents.Term " give jointly " and " combine " are included in the situation that there is not concrete time limit simultaneously or sequentially give two or more therapeutic agents.In certain embodiments, before giving the second therapeutic agent or afterwards (for example, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks ago), simultaneously or afterwards (for example, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks after) give first reagent.

[0188] According to an embodiment of the present invention, the immune system disease includes an autoimmune disease and / or a skin allergy disease.

[0189] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis and / or skin allergy disease.

[0190] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis, urticaria, skin inflammation and / or eczema.

[0191] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis and / or urticaria.

[0192] According to an embodiment of the present invention, the skin allergy disease includes urticaria, skin inflammation and / or eczema.

[0193] According to an embodiment of the present invention, the urticaria is chronic spontaneous urticaria.

[0194] Below, the scheme of the present invention will be explained in conjunction with embodiment.It will be understood by those skilled in the art that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention.In the embodiment, if specific technology or conditions are not indicated, the technology or conditions described in the literature in this area or the product instructions are used.The reagents or instruments used are not indicated by the manufacturer, and are all conventional products that can be obtained by commercial purchase.

[0195] For the preparation of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one (hereinafter referred to as the API or Compound (I)) in the following examples, see Scheme 29 and Example 32 in CN105837576A.

[0196] Example 1: Preparation of bulk drug capsules

[0197] 1.1 The components of Formulations 1 to 5 in the capsules are shown in Table 1. The preparation method of the capsules is as follows:

[0198] The API was crushed for 5 seconds and then dispersed with a 60-mesh sieve. The crushed API was then mixed with each excipient (except magnesium stearate), mixed at 15 rpm (which can be any speed within the range of 5-30 rpm) for 15 minutes (which can be any time within the range of 5-30 minutes), and then magnesium stearate was added, mixed at 5 rpm (which can be any speed within the range of 5-30 rpm) for 15 minutes (which can be any time within the range of 5-30 minutes), and finally the mixed drug was filled into a capsule (Suzhou Capsule Co., Ltd.) and the dissolution rate of the sample was measured. The capsules of the five prescriptions were then placed in a 60°C oven for a pre-stability test, and samples were taken after 10 days to measure the detection of related substances in the samples.

[0199] Table 1: Formulas of Prescriptions 1 to 5

[0200] 1.2 Dissolution rate detection

[0201] The dissolution rate of the prepared capsules was measured using the USP paddle method using a 1000 mL glass container with a lid. The capsules were placed in 900 mL of a solution at 37°C (±5°C) and pH 1.2 and stirred at 50 rpm. The dissolution results are shown in Figure 1. As can be seen, there was little difference between Formulations 1 to 5 of the present invention.

[0202] 1.3 Detection of related substances

[0203] Chromatographic conditions:

[0204] Chromatographic column: Agilent Zorbax SB-C18 (4.6 mm × 150 mm, 5 μm) or equivalent; column temperature: 30°C; flow rate: 1.0 mL / min; detection wavelength: 220 nm; injection volume: 10 μL; mobile phase A: pH 6.0 ammonium phosphate buffer solution; mobile phase B: acetonitrile; diluent: acetonitrile: purified water 50 / 50 (v / v).

[0205] Gradient elution program:

[0206] The test results of relevant substances are shown in Table 2. The results showed that, except for prescription 4, prescriptions 1 to 3 and prescription 5 all met the total impurity limit requirements.

[0207] Table 2: Impurity changes at 60℃ for 10 days

[0208] RRT: relative retention time

[0209] 1.4 The oral bioavailability of Formulations 1 and 3 capsules was further studied in beagle dogs. Six beagle dogs (3 male, 3 female) were provided by Beijing Marshall Biological Resources Co., Ltd. A single oral dose of 2 mg / kg was administered. Sampling was performed before administration and at 5, 15, 30, 1, 2, 3, 4, 6, 8, and 24 hours after administration.

[0210] From the in vivo bioavailability data in Table 3, it can be seen that the absolute oral bioavailability of Prescription 1 and Prescription 3 for beagle dogs is in the range of 22% to 26%.

[0211] Table 3: Oral bioavailability parameters of different capsule formulations in beagle dogs

[0212] Note: Cmax represents the peak concentration; T max represents the time to peak; AUC represents the area under the plasma concentration-time curve, where AUC 0-last Represents the area under the plasma drug concentration-time curve from time zero to the last time point, AUC 0-inf It represents the area under the plasma drug concentration-time curve from time zero to infinite time. 1 / 2 Indicates terminal elimination half-life, MRT 0-last Represents the average residence time from zero time to the last time point, MRT 0-inf represents the average residence time from time zero to time infinity. F(%)a represents the absolute bioavailability.

[0213] Example 2: Further screening of API capsule formulations containing different excipients

[0214] Prescription 6 was prepared by adding a certain amount of micropowdered silica gel to Prescription 1. The specific formula is shown in Table 4. The preparation method is similar to that in Example 1. The capsules of Prescription 6 were then placed in a 60°C oven for a preliminary stability test. After 10 days, samples were taken and tested for related substances (see Example 1 for the testing method). The test results are shown in Table 5. The results showed that, compared to Prescription 1 without micropowdered silica gel, the addition of micropowdered silica gel did not improve drug stability, but instead accelerated drug degradation.

[0215] Table 4: Formula of Prescription 6

[0216] Table 5: Impurity changes of prescription 6 after staking at 60℃ for 10 days

[0217] RRT: relative retention time

[0218] Example 3: Further screening of formulations of bulk drug capsules of different specifications

[0219] To accommodate capsules of varying sizes (or BTK inhibitor capsules), the dosages of the various components of Formulation 1 were further adjusted, as detailed in Table 6. The preparation method is described in Example 1, and the dissolution of the samples was determined (see Example 1 for the testing method). The test results, shown in Figure 2, revealed no significant difference in dissolution between the 5 mg, 50 mg, and 100 mg (Formulation C-2) capsules. Furthermore, the dissolution of Formulations C-1 and C-2 in a pH 1.2 medium was compared, revealing a 30-minute dissolution rate of 76.3% for Formulation C-1 and 79.3% for Formulation C-2, indicating minimal dissolution difference between the two formulations.

[0220] The capsules of each formulation were then placed in a 60°C oven for a preliminary stability test. After 10 days, samples were taken and assayed for related substances (see Example 1 for the assay method). The test results are shown in Table 7. The results showed that the impurity content of formulations C-1 and C-2 was not significantly different. In this example, the impurity changes of the 100 mg formulation are shown using formulation C-2 as an example. Specifically, the impurity growth of the 5 mg, 50 mg, and 100 mg capsules (using formulation C-2 as an example) after 10 days at 60°C was within the range of 2.4% to 2.5%, all within the required limit (≤5.0%).

[0221] Table 6: 5mg, 50mg and 100mg capsule formulations

[0222] Table 7: Impurity changes of Prescription A, Prescription B, and Prescription C-2 after 10 days of staking at 60°C

[0223] RRT: relative retention time

[0224] Test Example 1: In vivo efficacy study of prescription A, prescription B, prescription C-1, C-2 and API

[0225] 1. Mouse Model

[0226] 1.1 Evaluation of the in vivo efficacy model of collagen-induced arthritis (CIA) in mice

[0227] In this step, the solvent is prepared at a volume ratio of DMSO:40% HP-β-CD:water of 5:15:80 (10 ml of DMSO, 30 ml of 40% HP-β-CD, and 160 ml of MilliQ pure water are mixed and then divided into portions).

[0228] In this step, the API solution is prepared by weighing a predetermined amount of API, adding the calculated volume of DMSO, and vortexing until dissolved. Then, DMSO solution, 40% HP-β-CD, and MilliQ water are added (with a volume ratio of DMSO:40% HP-β-CD:water = 5:15:80). This solution is thoroughly mixed and diluted threefold to the desired dosing concentration to obtain the API solution at the specified dosing concentration.

[0229] In this step, the CC-292 solution was prepared by weighing a predetermined amount of CC-292 compound (98.7% purity), adding the calculated volume of DMSO, and vortexing until dissolved. DMSO solution, 40% HP-β-CD, and MilliQ water were then added (with a volume ratio of DMSO:40% HP-β-CD:water = 5:15:80). This solution was thoroughly mixed and diluted threefold to the desired dosing concentration to obtain a CC-292 solution at the desired dosing concentration.

[0230] The collagen-induced mouse arthritis model is a classic animal model used to evaluate the efficacy of drugs for rheumatoid arthritis (RA). Its pathogenesis and symptoms are clearly related to RA. Clinical symptoms of arthritis are induced in mice by injecting collagen emulsion into the tail. The specific steps are as follows:

[0231] DBA / 1 mice were randomly divided into 6 groups, 10 mice per group, excluding a blank control group (5 mice). Mice in the normal group did not require immunization; all other groups were immunized. The day of the first immunization was designated as day 0, and subsequent days were labeled sequentially. DBA / 1 mice were anesthetized with isoflurane and injected subcutaneously with 50 μL of the prepared collagen emulsion (containing 200 μg of CII) into the tail (2-3 cm from the base of the tail). On day 21, the same volume of collagen emulsion was injected into the tail using the same method.

[0232] On day 28, when the average clinical score reached 1 to 2, mice were randomly re-divided into four treatment groups (10 mice per group) and a blank vehicle control group (10 mice per group) based on body weight and score. The relevant dosage design of the drug substance and the control compound CC-292 was determined based on the results of the previous pilot study. The first group was a normal group (not fed any drugs or solvents); the second group was given a blank solvent control (the solvent was administered at 10 mL / kg); the third group was given CC-292 solution, with a CC-292 dose of 3 mg / kg (the concentration of CC-292 solution was 0.3 mg / mL, and the administration volume was 10 mL / kg); the fourth, fifth, and sixth groups were given API solution, with API doses of 1 mg / kg (the concentration of API solution was 0.1 mg / mL, and the administration volume was 10 mL / kg), 3 mg / kg (the concentration of API solution was 0.3 mg / mL, and the administration volume was 10 mL / kg), and 10 mg / kg (the concentration of API solution was 1 mg / mL, and the administration volume was 10 mL / kg), respectively. Dosing was once a day for a total of 14 days. The oral administration volume was 10 mL / kg. After the administration, the clinical score curve of each animal in each group was analyzed to calculate the area under the curve (AUC). The inhibition rate of each administration group relative to the blank solvent control was calculated based on the average AUC between groups.

[0233] Clinical Observation: From 7 days before immunization to day 21 after immunization, the basic health status and weight changes of DBA / 1 mice were observed daily (recorded twice a week). After day 22, the health status, disease incidence, and weight changes of the mice were observed daily (recorded every two days) until the end of the experiment.

[0234] Clinical Scoring: After boosting immunity, mice were observed daily for disease progression. Once disease onset (clinical signs of arthritis) developed, mice were scored on a scale of 0-4 based on the severity of the lesion (redness, swelling, joint deformity), with a maximum score of 4 for each limb and 16 for each animal. Scoring was performed at least three times weekly.

[0235] Pathology: On day 42, mice were euthanized. Both hind limbs were removed, soaked in 10% formalin, decalcified with formic acid, embedded in paraffin, sectioned, and stained with hematoxylin-eosin (HE). Microscopic photographs were taken and observed. The degree of joint damage was assessed based on four criteria: inflammatory cell infiltration, pannus formation, cartilage damage, and bone resorption, with a score of 0-4.

[0236] The experimental results showed that compared with the normal control group, the average body weight of each immunized group decreased significantly after administration. After day 33, the average body weight of the group treated with 1mg / kg of the API solution remained basically the same, while the average body weight of the groups treated with 3mg / kg and 10mg / kg of the API solution increased. The body weight of the 10mg / kg group showed significant differences compared with the blank solvent control group on days 37 and 40, demonstrating a good weight recovery effect.

[0237] The inflammatory inhibition rate was 65.5% in the 1 mg / kg API solution group, 82.4% in the 3 mg / kg API solution group, and 83.9% in the 10 mg / kg API solution group. All three doses showed highly significant differences compared to the blank vehicle control (p<0.001), demonstrating a dose-response relationship. The inflammatory inhibition rate was 29.1% in the 3 mg / kg CC-292 solution group, which showed no significant difference compared to the blank vehicle control.

[0238] Pathological studies revealed only mild inflammation in the foot joint bone tissue of the three dose groups (1, 3, and 10 mg / kg) of the API solution. Histopathological scores decreased with increasing dose in a dose-dependent manner, and there was a highly significant difference in histopathological scores compared to the blank vehicle control group. The reference control, CC-292 solution at 3 mg / kg, showed some inflammation and significant bone tissue damage, but there was no significant difference in histopathological scores compared to the blank vehicle control group.

[0239] 1.2 Evaluation of drug efficacy in the passive cutaneous anaphylaxis (PCA) animal model

[0240] Passive skin allergy testing, also known as PCA, is a local allergic reaction induced by antibodies that bind to tissues of the same or different species. The PCA animal model used in this application involves passive sensitization through the binding of IgE to specific receptors on skin mast cells. When challenged with an allergen, local mast cells release allergic mediators, increasing local vascular permeability. This is often used as a drug efficacy model for urticaria and can also demonstrate the anti-allergic effects of drugs during the development of skin inflammation and eczema. The specific steps are as follows:

[0241] In this step, the API solution is prepared using a solvent consisting of 5% DMSO (dimethyl sulfoxide) + 15% 40% HP-β-CD (hydroxypropyl-β-cyclodextrin) + 10% 0.4% Kolliphor EL (commercially available) + 70% water. A predetermined amount of API is weighed and dissolved in a calculated volume of DMSO. The solution is then thoroughly mixed with the calculated volume of HP-β-CD and Kolliphor EL in deionized water to obtain a drug solution at the desired dosing concentration.

[0242] In this step, prednisone was formulated with 0.5% CMC-Na (sodium carboxymethylcellulose).

[0243] In this step, cetirizine was prepared using a solvent consisting of 5% DMSO (dimethyl sulfoxide) + 15% 40% HP-β-CD (hydroxypropyl-β-cyclodextrin) + 10% 0.4% Kolliphor EL (commercially available) + 70% water. A certain amount of cetirizine was weighed and dissolved in the calculated volume of DMSO. The mixture was then thoroughly mixed with the calculated volume of HP-β-CD and Kolliphor EL plus deionized water to obtain the desired dosing concentration of cetirizine. (All cetirizine used in subsequent test cases was prepared with the solvent.)

[0244] In this step, LOU-064 is prepared using a solvent consisting of 5% DMSO (dimethyl sulfoxide) + 15% 40% HP-β-CD (hydroxypropyl-β-cyclodextrin) + 10% 0.4% Kolliphor EL (commercially available) + 70% water. A predetermined amount of LOU-064 is weighed and dissolved in the calculated volume of DMSO. The solution is then thoroughly mixed with the calculated volume of HP-β-CD and Kolliphor EL and deionized water to obtain a LOU-064 solution at the desired dosing concentration. The pH of LOU-064 is then adjusted to obtain a clear solution.

[0245] The PCA model in mice was induced using anti-DNP IgE. Specifically, BALB / c mice were divided into 9 groups, namely, a normal control group (no medication, injection or feeding of any solvent), a model group (no medication, injection or feeding of any solvent), a prednisone group (10 mg / kg, QD (once a day) for 3 consecutive days, where the concentration of prednisone was 1 mg / mL and the administration volume was 10 mL / kg), a cetirizine group (20 mg / kg, QD for 3 consecutive days, where the concentration of cetirizine was 2 mg / mL and the administration volume was 10 mL / kg), and a control group (10 mg / kg, QD for 3 consecutive days, where the concentration of cetirizine was 2 mg / mL and the administration volume was 10 mL / kg). / kg), low- and medium-dose groups of the test substance LOU-064 (15 and 45 mg / kg, administered twice a day (BID) for 3 consecutive days, where the concentrations of LOU-064 were 1.5 and 4.5 mg / mL, respectively, and the administration volume was 10 mL / kg), and low-, medium-, and high-dose groups of the drug solution (15, 45, and 90 mg / kg, administered BID for 3 consecutive days, where the concentrations of the drug solution were 1.5, 4.5, and 9 mg / mL, respectively, and the administration volume was 10 mL / kg). Each group had 9 mice, and the administration was performed by gavage for a total of 4 days. On the third day of administration, anti-DNP IgE (Sigma-Aldrich) was injected into the left ears of 8 groups of mice (no normal control group), and the right ears of 8 groups and the left and right ears of the normal control group were injected with the same volume of PBS to allow it to bind to mast cells. Then anti-DNP IgE injected after the 24h of the 4th day, with antigen (DNP-HAS, Sigma) and the mixed solution of pigment Evan's Blue (Sigma) (0.25mL / only, iv) be injected into tail vein (normal control group injects antigen and the pigment Evan's Blue mixed solution of same volume), antigen will react with the antibody that is attached on the mast cell and cause local allergic reaction, local vascular permeability raises, and pigment penetrates into tissue, by measuring the content of local pigment after 30min, judges reaction intensity.Collect left and right ear dye and extract, specific wavelength measures the absorbance of Evan's blue, calculate its content (referring to Table 8, wherein the right ear Evan's Blue concentration of each group and the normal control group left ear all have no significant differences) according to standard curve, assess the pharmacodynamic effect of each tested drug in PCA animal model.

[0246] Table 8

[0247] Experimental results showed that compared with the normal control group, the model group mice had significantly increased ear weight and Evan's Blue levels on the model side (left side). All three dose groups of the API significantly reduced Evan's Blue levels in the model animals' ears compared to the model group, demonstrating significant efficacy. The low and medium dose groups showed a dose-response relationship, with efficacy comparable to that of LOU-064 at the same dose. The low dose was comparable to prednisone and cetirizine. Therefore, the API demonstrated a promising therapeutic effect against anti-DNP IgE-induced passive cutaneous allergic reactions in mice.

[0248] 2. Patient clinical trials

[0249] 2.1 Test method

[0250] This test case recruited 96 healthy Chinese people aged 18-45 as subjects. The trial included 8 dose groups, with a total of 12 people in each dose group. They were randomly divided into groups, 10 of whom received the raw material drug capsule (i.e., the test group) and 2 received the placebo capsule (which did not contain the raw material drug ingredient, i.e., the control group or placebo group). The raw material drug capsules used the prescription A capsules, prescription B capsules, or prescription C-2 capsules prepared in Example 3; the placebo capsules used the prescription A' capsules, prescription B' capsules, or prescription C-2' capsules. The preparation of prescription A' capsules, prescription B' capsules, or prescription C-2' capsules specifically refers to the preparation method of Example 3, wherein the specific difference between prescription A' capsules and prescription A capsules is that they do not contain the raw material drug ingredient, the specific difference between prescription B' capsules and prescription B capsules is that they do not contain the raw material drug ingredient, and the specific difference between prescription C-2' capsules and prescription C-2 capsules is that they do not contain the raw material drug ingredient. The dosages involved in this example are all the amounts of the raw material drug.

[0251] Based on safety and exploratory factors, the human MRSD (maximum recommended starting dose) of the raw material capsule used in the test case was set at 10 mg, and the human maximum recommended dose was set at 800 mg. A total of 8 dose groups were set between the initial dose and the maximum dose (see Table 9 for the dose escalation plan for the clinical trial): 10 mg (the experimental group took 2 capsules of prescription A, and the placebo group took 2 capsules of prescription A'), 25 mg (the experimental group took 5 capsules of prescription A, and the placebo group took 5 capsules of prescription A'), 50 mg (the experimental group took 1 capsule of prescription B, and the placebo group took 1 capsule of prescription B'), 100 mg (the experimental group took 1 capsule of prescription C-2, and the placebo group took 1 capsule of prescription C-2') , 200 mg (the experimental group took 2 prescription C-2 capsules, and the placebo group took 2 prescription C-2' capsules), 400 mg (the experimental group took 4 prescription C-2 capsules, and the placebo group took 4 prescription C-2' capsules), 600 mg (the experimental group took 6 prescription C-2 capsules, and the placebo group took 6 prescription C-2' capsules), 800 mg (the experimental group took 8 prescription C-2 capsules, and the placebo group took 8 prescription C-2' capsules), and single-dose safety and tolerability tests were conducted on each group.

[0252] Subjects fasted for 10 hours before dosing and took a single oral dose of the API capsule or placebo capsule at the prescribed dose on the morning of the trial. No water was allowed within 2 hours of dosing, and no food was allowed within 4 hours of dosing. Blood sample collection: 3.0 ml of venous blood was collected before dosing (within 45 minutes) and at 10 minutes, 20 minutes, 0.5 hours, 1 hour, 1.5 hours, 1.75 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, 24 hours, 36 hours, 48 ​​hours, and 72 hours after dosing. Urine sample collection: Urine samples were collected before dosing (within 2 hours) and at 0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours, 12-16 hours, 16-24 hours, 24-48 hours, and 48-72 hours after dosing. Feces collection: Feces were collected before administration (within 3 days) and at 0-24h, 24-48h, and 48-72h after administration.

[0253] Table 9: Dose escalation plan for a Phase I single-dose clinical trial of the drug substance capsule

[0254] 2.2 Statistical analysis methods

[0255] Per-protocol population: All subjects who met the inclusion criteria, did not meet the exclusion criteria, had no major protocol deviations, and completed medication, pharmacokinetic and pharmacodynamic sampling, and safety assessments according to the protocol constituted the per-protocol population of this study.

[0256] 2.2.1 Statistical analysis of pharmacokinetics was performed using the protocol-based analysis. WinNonlin version 6.4 was used to process the plasma concentration data of the API capsules over time. The non-compartmental model was used to calculate the main pharmacokinetic parameters of each subject. The power function model was used to analyze the relationship between dose and C max , AUC 0-t linear relationship.

[0257] 2.2.2 Statistical analysis of pharmacodynamics was performed using the per-protocol set.

[0258] ELISA was used to detect the receptor occupancy of compound (I) in human peripheral blood mononuclear cell lysate. This analysis method is a relative quantitative determination of BTK in human peripheral blood mononuclear cells (PBMC) using ELISA.

[0259] PBMC lysate containing BTK was incubated with compound (I), with no compound (I) added as a control, and then incubated with biotinylated compound (I). The cells were then added to a streptavidin-coated plate. When compound (I) was co-incubated with the PBMC lysate, it bound to BTK, thereby preventing BTK from binding to the biotinylated compound (I). Since this complex was unable to bind to the plate, a response signal was not generated.

[0260] Rabbit anti-BTK primary antibody is incubated with the above samples, which will bind to BTK. Tetramethylbenzidine (TMB) is the substrate for the HRP-coupled anti-rabbit secondary antibody. The reaction is terminated with sulfuric acid. After color development, the absorbance is measured at a wavelength of 450 nm. 620 nm can be used for background correction. The amount of free BTK is proportional to the absorbance, thus indirectly detecting the BTK content. Data processing is as follows:

[0261] Free BTK (%) = 100% × [(S 样本X -S 样品X+化合物(I) ) / (S 第1天给药前 -S 第1天给药前+化合物(I) )]

[0262] Note: S 样本X : Indicates the absorbance value of the sample X to be tested;

[0263] S 样品X+化合物(I) : represents the absorbance value of the sample X after adding compound (I) [10uM], which serves as the background reference of the sample;

[0264] S 第1天给药前 : represents the signal value of the sample before the first administration;

[0265] S 第1天给药前+化合物(I): represents the absorbance value after adding compound (I) [10uM] to the sample before the first administration, which serves as the background reference of the sample.

[0266] BTK occupancy % = 100% - free BTK %.

[0267] The Chi-Square test was used to analyze the differences in BTK target site occupancy among the different dose groups; Logistic Regression was used to analyze the relationship between dose, blood drug concentration and BTK target site occupancy.

[0268] 2.2.3 Safety and Tolerability Assessment and Statistical Analysis

[0269] The safety data set included all subjects who received at least one dose and had post-dose safety data. Safety evaluation indicators included adverse events / adverse reactions, laboratory tests, electrocardiograms, vital signs, physical examinations, thyroid ultrasound, upper abdominal CT, and chest X-rays. All subjects in the placebo group were combined into one group. A safety analysis set was used, with safety indicators primarily described using statistical methods. Comparisons were performed before and after treatment within each treatment group, between each dose group, and between the treatment group and the placebo group.

[0270] 2.3 Results Analysis

[0271] 2.3.1 Pharmacokinetics

[0272] After a single dose of the API capsule was administered to healthy subjects, the CL / F, Vz / F, and T values ​​of the API capsules in the eight dose groups were compared. 1 / 2 , MRT 0-t , MRT 0-∞ and T max The difference was statistically significant (p<0.05), while the difference in CLr was not statistically significant (p>0.05) (see Table 10 for details). max =1.0740, within the range of 0.8 to 1.25. The slope of the linear equation βC max The 90% confidence interval of the drug was 1.0247-1.1234, and part of it fell within the judgment interval of 0.9491-1.0509, indicating that within the dose range of 10mg-800mg, the C max It has a linear pharmacokinetic trend (see Figure 3 and Table 11 for details). In addition, in the range of 10-100 mg (Figure 4 and Table 12) and 200-800 mg (Figure 5 and Table 13), AUC 0-t It shows a linear pharmacokinetic trend.

[0273] Table 10: Pharmacokinetic parameters of the API capsules after administration

[0274] Note: Data are expressed as mean ± standard deviation.

[0275] C max represents the peak concentration; T max represents the peak time; λ z represents the terminal elimination rate constant; AUC represents the area under the plasma concentration-time curve, where AUC 0-t The area under the blood drug concentration-time curve from time zero to the last quantifiable blood sampling point, AUC 0-∞ The area under the plasma drug concentration-time curve from time zero to infinite time, AUC _%Extrap The residual area percentage (AUC _%Extrap =[(AUC 0-∞ -AUC 0-t ) / AUC 0-∞ ]×100%). T 1 / 2 represents the terminal elimination half-life, V z / F represents the apparent volume of distribution in the terminal phase after non-intravenous administration, CL / F represents the apparent systemic clearance of the drug from plasma after oral administration, MRT last It represents the average residence time from zero to the lowest detectable blood drug concentration. INF_obs represents the mean residence time extrapolated from zero to infinity, and CLr represents the renal clearance rate of the drug from plasma.

[0276] Table 11: C of 10-800 mg capsules of the drug substance after a single dose max Linear evaluation results of the power function model with dose

[0277] Power function model formula: PK = α * dose β .

[0278] Judgment interval calculation formula: 1+Ln(θ L / Ln(r)<β<1+ln(θ H ) / ln(r); where r=D H / D L , D H Indicates high dose, D L Indicates low dose, θ L =0.8,θ H =1.25.

[0279] Table 12: AUC of 10-100 mg API capsules after single administration to healthy subjects 0-t Linear evaluation results of the power function model with dose

[0280] Power function model formula: PK = α * dose β .

[0281] Judgment interval calculation formula: 1+Ln(θ L / Ln(r)<β<1+ln(θ H ) / ln(r); where r=D H / D L , D H Indicates high dose, D L Indicates low dose, θ L =0.8,θ H =1.25.

[0282] Table 13: AUC of 200-800 mg API capsules after single administration in healthy subjects 0-t Linear evaluation results of the power function model with dose

[0283] Power function model formula: PK = α * dose β .

[0284] Judgment interval calculation formula: 1+Ln(θ L / Ln(r)<β<1+ln(θ H ) / ln(r); where r=D H / D L , D H Indicates high dose, D L Indicates low dose, θ L =0.8,θ H =1.25.

[0285] 2.3.2 Pharmacodynamics

[0286] After a single 10mg dose of the API capsule, the maximum BTK target occupancy was 58.93%. At doses of 25mg and above, the maximum BTK target occupancy approached 100% (see Figure 6 for details). The time to peak activity was 0.5-4 hours, decreasing with increasing dose. In the placebo group, BTK target occupancy was maintained between 20% and 30% for most of the time.

[0287] 2.3.3 Relationship between pharmacokinetics and pharmacodynamics

[0288] Based on the pharmacokinetic and pharmacodynamic data obtained for each dose, the quantitative relationship between pharmacokinetics and pharmacodynamics was analyzed.

[0289] The data fitting shows that at lower C max and AUC lastUnder these conditions, the BTK target occupancy rate can reach nearly 100% (see Figures 7-8 for details).

[0290] 2.3.4 Security

[0291] Twenty-nine of the 96 subjects experienced 44 adverse events (AEs), of which 43 were treatment-related adverse events (TEAEs), excluding one pre-dose adverse event. A total of 35 TEAEs occurred in 25 subjects (31.3%) in the experimental group, and 8 TEAEs occurred in 4 subjects (25%) in the placebo group. All TEAEs were Grade 1, except for one Grade 2 AE, anemia, in the placebo group (see Table 14 for details).

[0292] In the experimental group, except for two AEs (upper respiratory tract infection, eyelid surgery) that were treated with medication and one AE (upper respiratory tract infection) that was treated with a medical antipyretic patch, all other AEs required no intervention and resolved spontaneously to normal or baseline levels. With the exception of two AEs of nephrolithiasis that were clearly unrelated to the trial drug and resolved without change, all other AEs resolved. Nine (11.3%) subjects experienced 10 AEs that were deemed possibly related to the trial drug and were adverse reactions. The incidence of adverse events was higher in the 50, 100, 200, and 400 mg dose groups, all at 50%, while no adverse events occurred in the 800 mg dose group. The incidence of AEs in the other dose groups ranged from 10% to 30%. There was no apparent dose-related adverse event rate. In the placebo group, except for one AE (anemia) that was treated with medication and one AE (dizziness) that was treated with oral glucose, all other AEs required no intervention and resolved spontaneously to normal levels. All AEs resolved. The incidence of adverse reactions was 12.5% ​​(2 / 16). No SAEs (serious adverse events) occurred in this trial, and no AEs leading to withdrawal from the trial occurred (see Tables 15 and 16 for details).

[0293] Table 14: Summary of adverse event incidence during the trial

[0294] aThe severity of adverse reactions was graded according to CTACE version 4.03.

[0295] Table 15: Systemic adverse events in subjects after administration

[0296] Note: Adverse events were coded according to MedDRA V23.0.

[0297] Table 16: Adverse reactions caused by treatment

[0298] Note: Adverse events were coded according to MedDRA V23.0.

[0299] In summary, this test case studied the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral dose of API capsules in healthy adult subjects. The test results showed that within the range of a single dose of 10 to 800 mg, T max 1.03-2.00h, T 1 / 2 0.847-8.67h, C max The AUC is 46.1-5060 ng / mL, which increases with the dose, showing a linear pharmacokinetic trend. 0-t The BTK occupancy rate (CCR) ranged from 77.7 to 14,392 h*ng / m, increasing with dose within the 10mg-100mg and 200mg-800mg dose ranges, demonstrating a linear pharmacokinetic trend. CL / F was similar in the low-dose groups (10-50mg) and decreased with increasing dose. MRT was short, ranging from 1.53 to 4.25h, and slightly prolonged with increasing dose. The maximum BTK occupancy rate was 58.93% in the 10mg dose group and approached 100% in the 25mg and above dose groups. All AEs in the experimental groups were Grade 1 in severity, with only one Grade 2 AE occurring in the placebo group.

[0300] A Phase IIa clinical trial was designed to evaluate the efficacy and safety of compound (I) after 4 weeks of administration, with a primary efficacy analysis conducted in the fourth week. The Phase IIa clinical trial adopted a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of compound (I) in patients. The trial included patients who had been diagnosed with chronic spontaneous urticaria (CSU) at the time of randomization and met the following requirements: (1) itching and wheals had persisted for at least 6 weeks before screening, despite taking second-generation H1 antihistamines for CSU during this period; (2) the 7-day Urticaria Activity Score (UAS7) (range 0-42) was ≥16 points, the 7-day Wheal Severity Score (HSS7) (range 0-21) was ≥6 points, and the 7-day Itch Severity Score (ISS7) (range 0-21) was ≥6 points for 7 consecutive days (-8 to -2 days) before randomization; (3) the duration of CSU before screening was ≥6 months (defined as the onset of CSU confirmed by the investigator based on all available supportive records). After randomization, patients received compound (I) or placebo at a dose of 25 mg twice daily. Preliminary results were evaluated using the UAS7, 7-day pruritus severity score (ISS7), 7-day wheal severity score (HSS7), Dermatology Life Quality Index (DLQI), Urticaria Control Test (UCT), and Angioedema Activity Score (AAS7) scales to assess the improvement of patients' urticaria-related symptoms at week 4 or 5 after administration.

[0301] The Phase IIa trial will evaluate the compound (I)'s ability to improve urticaria-related symptoms in patients with chronic spontaneous urticaria, as well as its safety in patients.

[0302] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.

[0303] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.

Claims

1. A composition, characterized in that The invention comprises (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof.

2. The composition according to claim 1, characterized in that The content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 1 to 800 mg; Preferably, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 5 to 800 mg; Preferably, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 10 to 800 mg; Preferably, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is about 5 to 100 mg.

3. The composition according to claim 1, characterized in that The mass percentage of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof in the composition is about 1% to 40%, preferably about 4% to 35%.

4. The composition according to claim 1, characterized in that Further comprising pharmaceutically acceptable excipients; Optionally, the pharmaceutically acceptable excipients include fillers; Optionally, the filler comprises at least one of pregelatinized starch, mannitol, microcrystalline cellulose and lactose; Optionally, the filler is pregelatinized starch; Optionally, the filler is mannitol; Optionally, the filler is microcrystalline cellulose and / or mannitol; Optionally, the filler is microcrystalline cellulose and optionally mannitol; Optionally, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is about (1 to 40):(60 to 99); Preferably, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is about (4-35):(61-91); Preferably, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is about (16-35):(61-79); Preferably, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is approximately (4-10):(80-91).

5. The composition according to claim 4, characterized in that The pharmaceutically acceptable excipients further include at least one of a disintegrant, a lubricant, a surfactant and a binder; Optionally, the disintegrant is selected from at least one of cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch and cross-linked polyvinylpyrrolidone; Optionally, the disintegrant is cross-linked carboxymethyl cellulose sodium; Optionally, the lubricant is selected from at least one of magnesium stearate, calcium stearate and talc; Optionally, the lubricant is magnesium stearate; Optionally, the binder is selected from at least one of hydroxypropyl methylcellulose, povidone K30 and hydroxypropyl cellulose; Optionally, the binder comprises hypromellose and / or povidone K30; Optionally, the surfactant is selected from sodium lauryl sulfate and / or Tween 80; Optionally, the surfactant is sodium lauryl sulfate; Optionally, in the composition, the surfactant and the binder are present simultaneously; Optionally, the composition does not include micronized silica gel; Optionally, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the disintegrant is about (1-40):(1-10), preferably about (4-35):(4-6); Optionally, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the lubricant is about (1-40):(0.1-1), preferably about (4-35):(0.1-0.6); Optionally, the weight ratio of the surfactant to the binder is about (0.1-1):(1-5); Optionally, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the surfactant is about (1-40):(0.1-1), preferably about (4-35):(0.4-0.6); Optionally, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the binder is about (1 to 40):(1 to 5), preferably about (4 to 35):(1 to 2).

6. The composition according to any one of claims 1 to 5, characterized in that The composition is an oral preparation; Optionally, the oral formulation is a capsule or a tablet.

7. The composition according to claim 6, characterized in that The composition is a capsule; Optionally, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant, and a lubricant; Optionally, the composition does not include a surfactant; Optionally, the composition comprises: about 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 61 to 91 parts by weight of filler, about 4 to 6 parts by weight of a disintegrant, About 0.1 to 0.6 parts by weight of a lubricant; Optionally, the composition comprises: about 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 61 to 91 parts by weight of pregelatinized starch, About 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, About 0.1 to 0.6 parts by weight of magnesium stearate; Optionally, the composition comprises: about 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 88 to 91 parts by weight of mannitol, About 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, About 0.1 to 0.6 parts by weight of magnesium stearate; Optionally, the composition comprises: about 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 88 to 91 parts by weight of microcrystalline cellulose, About 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, About 0.1 to 0.6 parts by weight of magnesium stearate.

8. The composition according to claim 6, characterized in that The composition is a capsule; Optionally, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant, a binder, a surfactant and a lubricant; Optionally, the composition comprises: about 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 80 to 90 parts by weight of filler, about 4 to 6 parts by weight of a disintegrant, About 1 to 2 parts by weight of an adhesive, About 0.4 to 0.6 parts by weight of a surfactant, About 0.1 to 0.6 parts by weight of a lubricant; Optionally, the composition comprises: about 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 15 to 20 parts by weight of microcrystalline cellulose, About 65 to 70 parts by weight of mannitol, About 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, About 1 to 2 parts by weight of hypromellose, About 0.4 to 0.6 parts by weight of sodium lauryl sulfate, About 0.1 to 0.6 parts by weight of magnesium stearate.

9. A capsule, characterized in that It is composed of the following components: about 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, about 61 to 91 parts by weight of one of pregelatinized starch, mannitol and microcrystalline cellulose, About 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, About 0.1 to 0.6 parts by weight of magnesium stearate.

10. The capsule according to claim 9, characterized in that The capsule is composed of the following components: about 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 88 to 91 parts by weight of pregelatinized starch, About 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, About 0.4 to 0.6 parts by weight of magnesium stearate; Optionally, the capsule consists of the following components: about 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 88 to 91 parts by weight of microcrystalline cellulose, About 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, About 0.4 to 0.6 parts by weight of magnesium stearate; Optionally, the capsule consists of the following components: about 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 88 to 91 parts by weight of mannitol, About 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, About 0.4 to 0.6 parts by weight of magnesium stearate; Optionally, the capsule consists of the following components: about 16 to 17 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 78-79 parts by weight of pregelatinized starch, About 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, About 0.1 to 0.3 parts by weight of magnesium stearate; Optionally, the capsule consists of the following components: about 28 to 34 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 61 to 67 parts by weight of pregelatinized starch, About 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, About 0.1 to 0.3 parts by weight of magnesium stearate; Optionally, the capsule consists of the following components: about 28 to 29 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 65 to 67 parts by weight of pregelatinized starch, About 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, About 0.1 to 0.3 parts by weight of magnesium stearate; Optionally, the capsule consists of the following components: About 33 to 34 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 61 to 62 parts by weight of pregelatinized starch, About 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, About 0.1 to 0.3 parts by weight of magnesium stearate.

11. A capsule, characterized in that: It is composed of the following components: about 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, About 15 to 20 parts by weight of microcrystalline cellulose, About 65 to 70 parts by weight of mannitol, About 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, About 1 to 2 parts by weight of hypromellose, About 0.4 to 0.6 parts by weight of sodium lauryl sulfate, About 0.1 to 0.6 parts by weight of magnesium stearate.

12. Use of the composition according to any one of claims 1 to 8 or the capsule according to any one of claims 9 to 11 in the preparation of a medicament for treating and / or preventing immune system diseases.

13. Use of the composition according to any one of claims 1 to 8 or the capsule according to any one of claims 9 to 11 in treating and / or preventing immune system diseases.

14. The composition according to any one of claims 1 to 8 or the capsule according to any one of claims 9 to 11, for use in treating and / or preventing immune system diseases.

15. The use according to claims 12 to 14, characterized in that The immune system diseases include autoimmune diseases and / or skin allergy diseases; Optionally, the immune system disorder comprises rheumatoid arthritis, urticaria, skin inflammation and / or eczema; Optionally, the urticaria is chronic spontaneous urticaria.

16. A method for treating and / or preventing immune system diseases, characterized in that: include: A pharmaceutically acceptable amount of the composition according to any one of claims 1 to 8 or the capsule according to any one of claims 9 to 11 is administered to a subject.

17. The method according to claim 16, characterized in that The immune system diseases include autoimmune diseases and / or skin allergy diseases; Optionally, the immune system disorder comprises rheumatoid arthritis, urticaria, skin inflammation and / or eczema; Optionally, the urticaria is chronic spontaneous urticaria.

Citation Information

Patent Citations

  • Inhibitors of bruton's tyrosine kinase

    CN101805341A

  • BTK inhibitors

    CN105837576A

  • Polycyclic compound for inhibiting activity of Bruton's tyrosine kinase, pharmaceutical composition and application thereof

    CN114573586A

  • Compounds as kinase inhibitors

    CN115443277A

  • Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase

    US20220047588A1